2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

2466 Everolimus-based versus cyclosporine a-based GVHD prophylaxis after allogeneic HCT in adults: Reduced renal toxicity with comparable major transplant outcomes

Thomas Meyer, MD, Christopher Wippel2, Hauke Wilcken, MD3, Miriam Mozaffari Jovein, MD4, Jesus Duque Afonso, MD5, Kristina Maas-Bauer6, Ralph Wäsch, MD7, Justus Duyster8, Jürgen Finke, MD9, Robert Zeiser, MD, PhD10, Claudia Wehr11
1 Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
2 Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
3 Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
4 Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
5 Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
6 Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
7 Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
8 Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
9 Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
10 Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
11 Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
Background

Cyclosporine A (CSA) remains a cornerstone of graft-versus-host disease (GVHD) prophylaxis after allogeneic hematopoietic cell transplantation (alloHCT), but calcineurin inhibitor-related nephrotoxicity contributes to acute and persistent kidney dysfunction. Everolimus offers a calcineurin inhibitor-free immunosuppressive strategy with potentially lower renal toxicity. However, available evidence is limited to small prospective studies, selected patient populations, and treatment-switch cohorts, and concerns regarding adequate GVHD control remain. Large comparative data on upfront everolimus-based versus CSA-based prophylaxis are lacking. We therefore evaluated transplant outcomes and renal toxicity in a large single-center cohort of patients receiving either strategy.

Methods

Using a data-driven framework integrating routinely collected data, therapeutic-drug-monitoring records, and laboratory trajectories, we retrospectively analyzed patients aged 18 to 80 years undergoing first alloHCT at our center from 2009 to 2025. Exposure groups were defined using prophylaxis coding and measurable CSA or everolimus levels. Prophylaxis choice was at the treating physician’s discretion and was based mainly on baseline renal function. Patients with treatment switching and mixed exposure within the first 100 days post alloHCT were excluded.  

Overall survival was estimated by Kaplan-Meier analysis. Relapse or progression, clinically relevant GVHD, defined as acute GVHD grade II-IV or moderate to severe chronic GVHD, and AKI were analyzed by cumulative incidence with death as a competing event. Baseline eGFR was calculated using CKD-EPI 2021. AKI was captured by automated longitudinal creatinine surveillance using a KDIGO-based detection algorithm.

Multivariable Cox and cause-specific Cox models were used. A 1:1 Hungarian optimal matching without replacement served as sensitivity analysis, with balance assessed by standardized mean differences and outcomes analyzed using pair-clustered Cox models.

Results

Of 1,426 eligible patients, exclusion of those with treatment switching or no measurable drug exposure yielded an analysis cohort of 119 everolimus-only and 1,191 CSA-only patients.

Everolimus-treated patients were older at alloHCT, with a median age of 62 years (range, 19–79) versus 58 years (range, 18–79; p<0.01). They also had lower baseline eGFR, 74.5 versus 98.2 mL/min/1.73m², and higher creatinine, 1.04 versus 0.80 mg/dL, both p<0.001. Myeloid disease was similarly distributed, but AML was less frequent, 38.7% versus 47.6%, p=0.06, and MPN more frequent, 16.0% versus 8.4%, p=0.01, in the everolimus group.

Overall survival was comparable in unadjusted analysis, p=0.956. After adjustment for age, baseline eGFR, transplant year, disease status, ATLG, PT-CY, AML, MPN, lymphoma, CMV risk, donor mismatch, and female donor to male recipient transplantation, everolimus was neither associated with increased mortality (HR 1.02, 95% CI 0.73 to 1.43, p=0.912), nor with relapse or progression (HR 0.87, 95% CI 0.58 to 1.30, p=0.491), nor clinically relevant GVHD (HR 1.01, 95% CI 0.74 to 1.38, p=0.943).

Any AKI occurred in 74.8% (Everolimus-only) versus 92.9% (CSA-only), p<0.001. Everolimus remained associated with lower AKI risk after adjustment, HR 0.55, 95% CI 0.43 to 0.70, p<0.001, while AKI stage 2 or higher was not significantly reduced, HR 0.80, 95% CI 0.58 to 1.10, p=0.175. Longitudinal modeling showed a sustained eGFR decline of about 15 to 20 mL/min/1.73m² with CSA, whereas eGFR remained near baseline with everolimus.

The results of the MVA were confirmed in a matched-pair analysis: matching yielded 105 balanced pairs and confirmed comparable outcomes between Everolimus and CSA: overall survival (HR 1.14, p=0.558), relapse or progression (HR 1.28, p=0.382), and clinically relevant GVHD (HR 1.06, p=0.779). Everolimus remained associated with lower AKI risk, HR 0.54, 95% CI 0.39 to 0.73, p<0.001.

Conclusions

Leveraging an automated, longitudinal data approach, we analyzed, to our knowledge, the largest reported cohort of everolimus-treated alloHCT patients.

Despite preferential use in patients with impaired renal function and exclusion of patients switched from CSA because of possible renal toxicity, everolimus preserved major transplant outcomes while reducing AKI and maintaining eGFR. These findings support cyclosporine-free everolimus prophylaxis as a renal-sparing strategy and warrant prospective multicenter validation.

Thomas Meyer, MD: No relevant conflicts of interest to declare.